This is not the latest version of this item. The latest version can be found here.
Loading...
How can the potential of the duocarmycins be unlocked for cancer therapy?
Jukes, Zoë Morais, Goreti R. Pors, Klaus
Jukes, Zoë
Morais, Goreti R.
Pors, Klaus
Publication Date
2021-02
End of Embargo
Supervisor
Rights
Peer-Reviewed
Yes
Open Access status
closedAccess
Accepted for publication
Institution
Department
Awarded
Embargo end date
Collections
Additional title
Abstract
The duocarmycins belong to a class of agent that has fascinated scientists for over four decades. Their exquisite potency, unique mechanism of action, and efficacy in multidrug-resistant tumour models makes them attractive to medicinal chemists and drug hunters. However, despite great advances in fine-tuning biological activity through structure-activity relationship studies (SARS), no duocarmycin-based therapeutic has reached clinical approval. In this review, we provide an overview of the most promising strategies currently used and include both tumour-targeted prodrug approaches and antibody-directed technologies.
Version
No full-text in the repository
Citation
Jukes Z, Ribeiro Morais G, Loadman PM et al (2021) How can the potential of the duocarmycins be unlocked for cancer therapy? Drug Discovery Today. 26(2): 577-584.
Link to publisher’s version
Link to published version
Link to Version of Record
Type
Article